News | September 26, 2013

Siemens’ PETNET to Provide PET Radiotracer Services for US Oncology Network

Three-year agreement also extends to community practices engaged in McKesson Specialty Health’s Onmark Select Program

September 26, 2013 — Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved positron emission tomography (PET) radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.

The US Oncology Network is one of the nation’s largest networks of community-based oncology physicians, conducting roughly 60,000 PET scans annually. This agreement also extends to community practices engaged in McKesson Specialty Health’s Onmark Select Program.

Under the agreement, Siemens’ PETNET Solutions also will provide The US Oncology Network-affiliated practices and Onmark Select Practices with its comprehensive portfolio of products and services to expand patient access to premium PET imaging services.

PET/CT imaging also plays a major role in the evaluation and treatment monitoring of cancer patients. The high contrast and sharp delineation of molecular resolution made possible through PET imaging is vital for tumor identification and treatment, enabling physicians to determine whether cancer is present, whether it has metastasized and whether treatment is effective. Because PET imaging measures molecular activity, it can accurately characterize a tumor’s malignant or benign state as well as confirm metastasis – enabling proper staging and facilitating suitable treatment protocols.

Siemens’ PETNET Solutions provides patient access to radiopharmaceuticals for the evaluation of cancer through PET. McKesson Specialty Health and Siemens’ PETNET Solutions share a common vision of expanding patient access to PET imaging services for cancer patients.

For more information: www.usa.siemens.com/healthcare

 

Related Content

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
News | Radiopharmaceuticals and Tracers | January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
Overlay Init